Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics (NASDAQ: FOLD ) popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals (NASDAQ: BOTA ) collapsed 34% upon receiving a stop-work order from the Biomedical Advanced Research and Development Authority (BARDA). While a single government contract for developing influenza vaccines may not sound like a huge potential issue for a company, the contract in question has generated the majority of Biota's revenue since the company won the contract in 2011.
Check out the video below for more information on the two stocks and how investors may want to respond to these major movers.
Even with today's massive increase, Amicus may have serious trouble keeping up with this top 2014 stock
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.